secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2022-01-20T23:59:59+00:00
Accession:  0001193125-22-013774
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon appoints Dr. Bettina Cockroft to board of directors
-----------------------------------------------------------

- Dr. Cockroft is SVP and CMO of Sangamo Therapeutics, effective immediately.
- Appointed as Class III director with term expiring at 2023 annual meeting.
- Receives $35,000 annual retainer, initial option for 20,000 shares, and annual grant for 10,000 shares.
- She brings nearly 20 years of clinical development experience in neurodegenerative and movement disorders.
- Annexon highlights her expertise as it advances complement-mediated therapies in GBS and Huntington's disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312522013774/0001193125-22-013774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312522013774/d477760d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-013774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer